TABLE 2

Outcomes of patients with bloodstream infection caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae according to therapya

CharacteristicNo. (%) of patients with indicated treatment
Empirical therapy cohort (n = 174)Definitive therapy cohort (n = 251)
Carbapenem; n = 126BLBLI; n = 48PCarbapenem; n = 234BLBLI; n = 17P
ICU admission30 (23.8)7 (14.5)0.2544 (18.8)2 (11.7)0.74
30-day case fatality rate17 (13.4)10 (20.8)0.3337 (15.8)1 (5.8)0.99
14-day case fatality rate12 (9.5)7 (14.5)0.4923 (9.8)1 (5.8)0.99
7-day case fatality rate6 (4.7)2 (4.1)0.9911 (4.7)0NA
Relapse of bloodstream infection02 (4.1)NA4 (1.7)0NA
Persistent bloodstream infection5 (3.9)5 (10.4)0.1311 (4.7)3 (17.6)0.059
Colonization/infection by resistant bacteria8 (6.3)1 (2)0.2815 (6.4)1 (5.8)0.99
Superinfection11 (8.7)2 (4.1)0.5121 (8.9)2 (11.1)0.68
  • a ICU, intensive care unit; NA, not applicable.